Tag Archives: PHA

PR Newswire

Enamine implements CDD Vault to digitalize its integrated medicinal chemistry, ADME-PK and screening services

Leave a comment

The company’s expansion in the biological assay space aided by the data platform

SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 — Enamine, a leading provider of R&D Services as well as Screening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, announced today that it had implemented Collaborative Drug Discovery’s CDD Vault to manage its biological assay data. The platform will enable seamless and secure exchange of information between Enamine and its partners in pharmaceuticals, biotechs and other organizations conducting drug discovery research.

Enamine offers a sizable portfolio of R&D services to support complex medicinal chemistry and biology programs. These services include a wide range of bioanalytical, molecular screening and other custom biological study services.

The company is undergoing an ambitious expansion in the markets it serves by adding expert scientists to the team and adopting new technologies such as CDD Vault.

The CDD Vault hosted research data management platform will complement the suite of advanced software tools already deployed at Enamine. CDD Vault enables users to store, manage, and analyze chemical compounds and biological assay data. Enamine’s extensive collaborations across the globe will benefit from the intuitive, collaborative platform and secure data sharing mechanism.

"Managing biological assay data with CDD Vault is straightforward, avoids mistakes and helps with the overall quality control of the studies. The platform enables us to share data with partners in real-time and discuss results and propose follow-ups.  We are laser focussed on providing accurate results, added know-how and superior value to our customers," said Dr. Petro Borysko, Director of Biology at Enamine, "We have integrated CDD Vault via the API with our in-house software, which makes the whole data management process very smooth and easy, maximizing the quality of the data".

"Enamine has one of the most impressive compound libraries in the world, and we are delighted to support the expansion of their biological study services. Their world-class team of biologists combined with advanced laboratories can greatly accelerate drug discovery programs", said Dr. Mariana Vaschetto, CDD’s Head of Operations EMEA/LATAM, adding that, "The collaborative nature of CDD Vault makes it the ideal platform for CROs. At the same time, its ease of use allows fast user adoption, an essential requirement for service-oriented organizations."

About Enamine

Established in Kyiv in 1991, Enamine (https://enamine.net) is a global leading designer and largest producer of building blocks, fragments and screening libraries. Enamine provides expertise in advanced organic synthesis, library synthesis, medicinal chemistry. In 2011 Enamine established a pre-clinical service unit including ADME, in-vivo PK studies and High Throughput Screening allowing the company to tackle since that time fully integrated or à-la-carte research programs.

About Collaborative Drug Discovery, Inc.

CDD’s (https://www.collaborativedrug.com/) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Logo – https://mma.prnasia.com/media2/1177967/Collaborative_Drug_Discovery_Logo.jpg?p=medium600  

Related Links :

http://www.collaborativedrug.com

PR Newswire

Insilico enters into a collaboration with APRINOIA to apply novel generative AI-powered system to discover novel compounds for neurodegenerative diseases

Leave a comment

TAIPEI, Taiwan, Dec. 30, 2020 —  Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.

Insilico partners with APRINOIA
Insilico partners with APRINOIA

With a mission to accelerate drug discovery and development, Insilico Medicine has been breaking new grounds with its next-generation AI technologies and expanding international partnerships in the US, Europe and Asia Pacific Region.

"APRINOIA discovers and develops first-in-class diagnostics and therapeutics that can be broadly applied as PET tracers in the field of neurodegenerative diseases. We are glad to collaborate with APRINOIA, where we will apply our Chemistry42 suite to design a new generation of PET tracers with desired properties. Through this collaboration, we will further demonstrate the universality of our AI-powered generative chemistry platform," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan.

"We are excited to initiate the collaboration with Insilico to enrich APRINOIA’s proprietary collection of compounds for neurodegeneration," said Dr. Ming-Kuei Jang, CEO of APRINOIA. "Early diagnosis is critical for disease management. Our initial focus is to discover novel imaging PET tracers to quantify and visualize pathologies of abnormal proteins in the brain. With Insilico’s AI-powered platform, we are hoping to shorten the time from lab to clinics to benefit patients and in the medical communities."

By leveraging an integrated AI-driven drug discovery approach, Insilico Medicine provides APRINOIA Therapeutics with an effective, rational, external auxiliary solution for driving programs forward. The partnership between APRINOIA and Insilico will include an upfront fee and performance-based milestones.

About APRINOIA Therapeutics
APRINOIA Therapeutics is currently advancing a pipeline featuring diagnostic and therapeutic programs, collectively targeting brain disorders associated with abnormal accumulation of pathological proteins, including tau and alpha-synuclein, from its proprietary small molecule and antibody discovery platforms. APRINOIA is committed to building a pipeline of innovative products, as well as developing partnership with global and regional pharmaceutical companies to accelerate its programs. The company currently has operations in Taipei, Suzhou, Shanghai, Tokyo, and Boston.

Website: www.aprinoia.com

About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards.

Website: http://insilico.com/

Media Contact
For further information, images or interviews, please contact:
ai@insilico.com

Related Links :

http://insilico.com

PR Newswire

Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud

Leave a comment

The Tony Blair Institute for Global Change and Oracle partner with African governments to manage large-scale vaccination programs in the cloud – over 73,000 people vaccinated and registered in the first 8 days in Ghana

LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 — The Tony Blair Institute (TBI) and Oracle have brought cloud technology to Africa to manage public health programs. Initially, Ghana, Rwanda, and Sierra Leone will use the new Oracle Health Management System to create electronic health records for their vaccination programs for yellow fever, HPV, polio, measles, and COVID-19, as soon as that vaccine is distributed to Africa. TBI and Oracle are in discussions with more than thirty other countries in Africa, Asia, Europe, and North America that are evaluating using the same cloud system to manage their COVID-19 vaccination programs.  

jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”
 

jwplayer(‘myplayer1’).setup({file: ‘https://www.youtube.com/watch?v=k4oZC3yjolI’, image: ‘http://www.prnasia.com/video_capture/3200226_AE00226_1.jpg’, autostart:’false’, aspectratio: ’16:9′, stretching : ‘fill’, width: ‘600’, height: ‘338’});

"Since February of this year, the Africa Union and Member States have worked tirelessly together to address the impact of COVID-19 on the continent," said Dr. John Nkengasong, Director of the Africa Centres for Disease Control and Prevention. "As the COVID-19 pandemic continues, partnerships such as this one with Oracle, TBI and various governments are critical to the strengthening of Member State public health institutions, not only to incorporate innovative technology but to proactively and urgently harmonize the collection and sharing of important testing data across the continent."

TBI has been providing policy advice and hands-on support to African governments as they tackle complex COVID-19 challenges. To address these challenges, TBI partnered with Oracle to deliver cloud technology to digitize and unify national health data starting with the management of vaccinations. The Oracle Health Management System creates an electronic health record in a cloud database for every person as they are vaccinated. This highly-secure system can be quickly configured to interoperate with each country’s existing technology and meet their most stringent data sovereignty requirements. Participating countries will have access and support for the system, free of charge, for the next ten years.

"This is an immensely exciting and potentially ground-breaking initiative for recording information on all disease vaccinations and treatments in African nations," said Tony Blair, Executive Chairman of TBI and the former Prime Minister of Great Britain and Northern Ireland. "Though Africa has coped well with COVID-19, it still needs to be part of international efforts to control the disease, including for international travel. That means vaccination of at least a significant portion of the population, requiring the highest quality data system so that everyone’s vaccine experience is recorded. Oracle can provide that system with data securely stored and owned by each country and is prepared to do so as part of a global philanthropic partnership.

We will be living with COVID-19 for some years, and the recording of data will be vital in managing its impact and spread. And one thing is clear from this crisis: applying new technology solutions has applications for the digitization of the entire economy and is crucial for the acceleration of African development. This initiative is a great test case, and my Institute is proud to be part of it."  

"The Oracle Health Management System is currently being used by the U.S. government and large healthcare and research organizations to monitor COVID-19 patient symptoms, responses to treatments, and to screen volunteers for COVID-19 vaccine clinical trials," said Oracle Chairman and CTO Larry Ellison. "By working with Tony and his team over a period of a few months, we were able to deliver the exact same 21st century cloud technology to Ghana, Rwanda, and Sierra Leone. This is the first time vaccine data has been stored in a cloud database on a national scale. Africa is leading the way."

Bringing Cloud Technology for Electronic Health Records to Africa

Ghana is now using the system to manage its yellow fever vaccine program and will follow with COVID-19 once that vaccine is distributed in Africa.

Ghana President Nana Akufo-Addo said, "We have learned many lessons from this pandemic. The most obvious is that we have to urgently fortify our public health systems. This strategic partnership with Oracle and TBI is evidence of our drive to digitalize Ghana’s health systems for our people’s benefit."

"The move from Ghana’s current paper-based vaccination campaign records to digital data management using the Oracle platform will enable our data to be easily accessible by authorized persons. The data will be more secure, and there will be no worry about lost cards as people travel," added Dr. Kwame Amponsa-Achiano, Expanded Programme on Immunization, Ghana Health Service.

Hear more from Dr. Kwane Amponsa-Achiano at https://bit.ly/3fntnZf.

Rwanda has prepared its system to support its HPV vaccine administration as soon as secondary schools reopen, with plans to support COVID-19 vaccinations and an immunity pass for citizens in the future.

President of Rwanda, Paul Kagame called for a resilient health system as the best defense against future pandemics: "A COVID-19 vaccine will be a critical tool, and Africa must be able to access to its fair share of a vaccine once it is available. This partnership will deliver an innovative digital vaccine e-registry that signals the continent’s readiness to deploy the vaccine and to safely reopen our economies to trade and tourism."

Sierra Leone is preparing to use the system to create digital vaccination records when its next routine Expanded Program on Immunization (EPI) campaign begins. EPI is a global initiative to vaccinate for polio, diphtheria, tuberculosis, pertussis, measles, and tetanus. It is estimated to prevent two to three million childhood deaths globally each year from these diseases. Sierra Leone’s EPI program reportedly covers 95% of eligible children in that country.

Chief Innovation Officer and Minister of Education of Sierra Leone, Dr. David Moinina Sengeh, noted, "The Government of Sierra Leone is committed to utilizing technology and innovation – digitizing services to improve service delivery for its citizens. Using our experience from Ebola, we were able to put together a robust National COVID-19 Response plan, which has technology, data, and innovation as core enablers. This collaboration with Oracle and TBI is significant not only for dealing with COVID-19 and broader health needs, such as EPI vaccinations but will be a key step in our country’s mission of digitization for all."

As countries begin vaccinating people for COVID-19, the Oracle Health Management System can be used to automatically create an electronic health record for every person vaccinated.  Once the COVID-19 vaccine is available, the Oracle Health Management System will track immunizations and provide recipients with a Digital Quick Response (QR) code. These QR codes will help Africa reopen its borders and economies by providing citizens the proof of immunization needed to move freely for work and travel.

About the Tony Blair Institute for Global Change
TBI’s Government Advisory Practice directly supports leaders in their on-the-ground fight against COVID-19, and our Policy Futures unit is delivering analysis and advice to help countries mitigate economic impact, source essential equipment, harness the power of technology and position themselves for the rebuilding to come.

The tech revolution can be accelerated in Africa and other emerging and developing countries, not only to deal with COVID-19, but also embedding robust health care systems that will benefit citizens, and beyond health, to digitize public services and the economy.

About Oracle
Oracle offers suites of integrated applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

Boy in Ghana receiving a yellow-fever vaccination. Credit: The Tony Blair Institute for Global Change
Boy in Ghana receiving a yellow-fever vaccination. Credit: The Tony Blair Institute for Global Change

   

Video – https://www.youtube.com/watch?v=k4oZC3yjolI
Photo – https://techent.tv/wp-content/uploads/2020/11/tony-blair-institute-and-oracle-launch-africa-vaccine-management-in-the-cloud-1.jpg
Logo – https://techent.tv/wp-content/uploads/2020/11/tony-blair-institute-and-oracle-launch-africa-vaccine-management-in-the-cloud.jpg

Related Links :

http://www.oracle.com

PR Newswire

The fourth CIIE begins taking stall reservations from exhibitors

Leave a comment

SHANGHAI, Nov. 13, 2020 — Some exhibitors planning to attend the fourth China International Import Expo (CIIE) next year started to reserve their stalls on Nov 8. This is the first time that the CIIE has offered such an option.

Five dairy companies – Fonterra, Mille, Ausnutria, Yashily and Saputo – marked their reserved booths on a map of the fourth CIIE.

Companies showcasing products at the beauty makeup section of the Consumer Goods Exhibition Area, pharmaceutical products section of the Medical Equipment & Healthcare Products Exhibition Area, and dairy products section of the Food and Agricultural Exhibition Area will receive priority when reserving their exhibition stalls, as part of new measures adopted by the fourth CIIE.

"We hope to explore a mechanism where exhibitors can choose their preferred stalls on their own starting from next year," said a worker responsible for recruiting exhibitors to the fourth CIIE.

He added that exhibitors can decide earlier to attend the expo and make preparations in advance.

The stalls at the CIIE’s Food and Agricultural Products Area have always proved to be popular among exhibitors wanting to make reservations.

The exhibition area occupied by dairy companies at the third CIIE was nearly 10,000 square meters, with six of the top eight dairy companies in the world taking part in.

The fourth CIIE’s Food and Agricultural Products Area has remained popular, with over 10 dairy companies having signed on to attend and their signed exhibition areas surpassing a total area of 5,000 square meters.

Over 120 beauty makeup and daily chemical companies have been invited to make reservations for exhibition stalls at the fourth CIIE, and many of them are currently signing agreements or making down payments.

Due to high exhibitor demand, the fourth CIIE’s beauty makeup and daily chemical product section is expected to expand to 25,000 square meters from 20,000 sq m this year.

China is the largest and most significant market for Fonterra. The CIIE has provided development opportunities for them, said Han Li, Vice-President of Fonterra Greater China, explaining why they continue to attend the expo and make reservations.

The fourth CIIE began taking applications from business exhibitors on Sept 28. It will set up six business exhibition areas: Intelligent Industry & Information Technology, Consumer Goods, Automobile, Food and Agricultural Products, Medical Equipment & Healthcare Products and Trade in Services.

Contact：Ms. Nie Qingxin

Tel.：0086-21-67008870/67008988

PR Newswire

AlpVision to offer free of charge security feature to protect COVID-19 relevant medicines against counterfeiting

Leave a comment

VEVEY, Switzerland, Nov. 13, 2020 — On November 13th, 2020, AlpVision is launching the "AlpVision COVID-19 Initiative" helping pharmaceutical companies to protect COVID-19 relevant medicines against counterfeiting.

Authentication using smartphones
Authentication using smartphones

COVID-19 has caused not only a worldwide health crisis, but also created unprecedented economic challenges. In response, AlpVision has decided to launch the "AlpVision COVID-19 Initiative". The initiative supports pharmaceutical companies by providing them for free with the necessary tools to protect COVID-19 relevant medicines and vaccines against counterfeiting.

To do so, AlpVision will provide pharmaceutical companies and their suppliers with all necessary tools to deploy the Cryptoglyph on their packaging. The AlpVision Cryptoglyph is a digital security feature which can be implemented and deployed within just a few weeks. The Cryptoglyph is invisible to the human eye and authentication of a product protected with a Cryptoglyph is done using a regular smartphone. Securing of packaging with a Cryptoglyph is very easy as it neither changes the standard production process, nor requires additional consumables. In addition, the smartphone applications connect to AlpVision’s Brand Monitoring System (BMS), a centralized server platform through which pharmaceutical companies are able to monitor in real-time product authentication activities and gain important insight into counterfeiting activities.

The "AlpVision COVID-19 Initiative" starts on November 13th, 2020, and subscription will run for an initial period of three months. Participating companies will be able to protect their COVID-19 relevant products with zero additional cost for the authentication feature. AlpVision will provide this service gratuitously until the pandemic is officially declared as ended by the World Health Organization. Companies interested in participating in the initiative are invited to contact AlpVision. More information can be found online at www.alpvision.com/Covid/.

ALPVISION – MORE THAN ANTI-COUNTERFEIT SOLUTIONS

AlpVision was founded in 2001 and is the world’s leader in digital anti-counterfeiting technologies for product authentication and counterfeit protection. AlpVision’s digital anti-counterfeiting solutions for product authentication are applicable to a wide variety of items, including packaging and labelling, plastic and metal products, and high-value documents. AlpVision anti-counterfeiting solutions are commercialized worldwide under license agreements as entirely customizable turnkey computerized systems. Today AlpVision protects over 30 billion of products each year. More information is available at www.alpvision.com. Join us on LinkedIn and follow us on Twitter.

Cryptoglyph and AlpVision are registered trademarks of AlpVision SA. Smart Embossing, AlpVision Fingerprint® and Krypsos are trademarks of AlpVision SA.

Contact:

Martin Kutter 
+41 21 948 6464  
avinfo-20@alpvision.com

Photo – https://techent.tv/wp-content/uploads/2020/11/alpvision-to-offer-free-of-charge-security-feature-to-protect-covid-19-relevant-medicines-against-counterfeiting.jpg
Logo – https://techent.tv/wp-content/uploads/2020/11/alpvision-to-offer-free-of-charge-security-feature-to-protect-covid-19-relevant-medicines-against-counterfeiting-2.jpg

  

Related Links :

http://www.alpvision.com

PR Newswire

Clarivate Expands International Real-World Data Offering with Addition of Techtrials Brazilian Dataset

Leave a comment

Partnership to provide life science, healthcare and research professionals with comprehensive RWD capturing approximately 80% of the Brazilian population

LONDON, Nov. 2, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the expansion of international real-world data offerings through its partnership with Techtrials Pesquisa e Tecnologia Ltda (Techtrials), the leading healthcare real-world data (RWD) provider in Brazil. The new partnership will provide customers with comprehensive RWD capturing approximately 80% of the Brazilian population.

As part of the three-year partnership, Clarivate customers can access the largest integrated real-world database in Brazil to address the most pressing questions related to epidemiological, clinical and pharmacoeconomic outcomes. The dataset features in-depth, clinically structured, anonymized data of billions of records with more than 195 million patients in the public and private market as well as claims, electronic medical records, registry and lab data. The comprehensive Techtrials real-world data paired with the expertise, information and insights that power DRG healthcare products and services, will allow global researchers to access, synthesize and analyze critical data.

The Techtrials dataset will be available to life sciences companies internationally, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases.  Clients can choose from an array of delivery options depending on their resource needs and expertise, including: commercial targeting; patient population & market sizing; patient journey; therapeutic area assessments; disease burden analysis; health economics and outcomes research and more.

As the world’s 11th largest pharmaceutical market, Brazil spends 9.5 percent of GDP on healthcare – providing universal healthcare to its population.1 Multinational pharmaceutical companies continue to invest and expand operations in Brazil, with market researchers anticipating spending to increase at a compound annual growth rate of 7% to 10% from 2018–2022.2 Clarivate recognizes the ever-increasing need for customers within the Latin American market to have insights-ready RWD on a real-time basis to help drive and inform decision-making.

Ken McLaren, SVP & GM of Data, Analytics and Insights for Clarivate, said: "We appreciate the complexity of healthcare and the diversity of decisions its leaders must make, especially in an international context. We look forward to partnering with an organization like Techtrials to help our customers understand and drive decision-making with confidence in the high growth, high interest Brazilian market."

Douglas Andreas Valverde, CEO, Techtrials, said: "As a regional innovation leader for data solutions and real-world evidence, we offer a unique mix of capabilities and proprietary technology, providing valuable clinical and real-world evidence insights to support the efforts of pharmaceutical, healthcare and government agencies. We are proud to partner with Clarivate to reach international industry stakeholders who need to act and make critical decisions in their daily operations."

The Brazilian RWD offering features insights, including: new professionals per institution; variation of patients per period; procedures; workload by institution; comprehensive disease, epidemiology and market knowledge; drug use by specialty; outcomes, hospitalizations, surgeries and sub-procedures; hospital and comorbidities and more. The incorporation of Techtrials data further reinforces the expertise provided by Clarivate to support customers across the entire drug, device and medical technology lifecycles.

To learn more, visit https://clarivate.com/drg/real-world-data.

About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

Media Contact
Catherine Daniel
media.enquiries@clarivate.com

1National Health Account (NHA) Indicators 2020. Source: Global Health Expenditure Database (GHED) of the World Health Organization.
2"Brazil: Commercialization Outlook, Global Market Access Solutions" 2020. Source: DRG, part of Clarivate

Logo – https://techent.tv/wp-content/uploads/2020/11/clarivate-expands-international-real-world-data-offering-with-addition-of-techtrials-brazilian-dataset.jpg

Related Links :

Home
PR Newswire

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Leave a comment

HONG KONG, Oct. 15, 2020 — Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico’s state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho’s expertise in drug development, aimed to extend the human healthspan.

Insilico partners with Taisho
Insilico partners with Taisho

"We’re delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho’s validation platform to explore the new space of anti-aging solutions," said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico’s co-ownership of the successfully developed programs under agreed payment.

"It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/

Media Contact

For further information, images or interviews, please contact:

ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Photo – https://mma.prnasia.com/media2/1312850/insilico_taisho.jpg?p=medium600  

Related Links :

http://insilico.com

PR Newswire

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

Leave a comment

Allscripts enables enterprise-level, interoperability-aided EMR workflow adjustments and the subsequent clinical decision-making from a single window

SANTA CLARA, Calif., Oct. 7, 2020 — Frost & Sullivan has identified Allscripts, a global healthcare IT company, as a growth and innovation top-performing leader in the Frost Radar™: US Healthcare Data Interoperability Market, 2020. Allscripts demonstrates superior interoperability across the entire HIT ecosystem by enabling the direct integration of third-party clinical decision support applications into the company’s platforms through on-premise or cloud deployment models.

Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market
Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market

The global healthcare data interoperability market is valued at $4.92 billion in 2020, and the US market is projected to contribute $3.3 billion (67.07%). Frost & Sullivan expects departmental interoperability within a health system to remain significant during the COVID-19 pandemic because it facilitates the personalization of administrative, clinical, and financial intervention based on patients’ history of COVID-19 or proximity to regional hotspots.

To download the complimentary Frost Radar, please access: http://frost.ly/4mp.

"During and post-COVID-19, Allscripts’ EMR, patient engagement, population health management (PHM), and revenue cycle management (RCM) solutions can be made part of an integrated offering that can interface with external health systems, solutions and service providers, at scale and in near-real-time," said Koustav Chatterjee, Healthcare Industry Principal at Frost & Sullivan.

"We are honored to be recognized by Frost & Sullivan as an industry pioneer, as this ranking reflects our leadership in innovation and interoperability across the healthcare continuum," said Paul Black, Allscripts Chief Executive Officer. "Each day, our mission is to connect care across patient communities around the globe. At Allscripts, we believe healthcare should be Open, for Everyone™."

Frost & Sullivan found that Allscripts has practical, high-impact services that attain higher levels of scale in the United States. Allscripts is poised for further growth by:

  • Opening API initiatives, which are powered by the largest group of third-party API developers (4,000) in the US.
  • Augmenting its EMR capabilities and integrating cognitive interoperability standards across its HIT workflows.
  • Pioneering enterprise-level, interoperability-aided EMR (Sunrise EMR, TouchWorks® EHR) workflow adjustments and the subsequent clinical decision-making from a single window.
  • Incorporating SMART on FHIR (Fast Healthcare Interoperability Resources) across its product portfolio and strongly advocating the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) provisions (under the 21st Century Cures Act) for interoperability and patient access management.

Frost Radar™: US Healthcare Data Interoperability Market, 2020 provides results from an in-depth analysis built on a 360-degree research methodology where over 50 companies were evaluated. The team of industry analysts identified 11 industry leaders excelling at innovation, most poised for growth and ripe for investment, and recognizes them in the Frost Radar with insight into their innovative offerings, projected growth rates, strengths, and opportunities for the future.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Mariana Fernandez
Corporate Communications
Phone: +1 (210) 348.1012
Email: mariana.fernandez@frost.com

https://www.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/frost-sullivan-recognizes-allscripts-as-a-growth-and-innovation-leader-in-the-united-states-healthcare-data-interoperability-market.jpg 

Related Links :

Frost New Home page v2

PR Newswire

Pharmalutions And Movilitas.Cloud Deliver Serialization Solutions for the Asia-Pacific Region

Leave a comment

Partnership Provides Greater Access to End-To-End Serialization and Track & Trace Solutions

COLUMBIA, Md., Sept. 11, 2020 — Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while improving operational efficiencies to deliver safer pharmaceuticals to patients.

Several countries in the Asia-Pacific region, such as Indonesia, Thailand and Malaysia, have already established or announced the introduction of serialization regulations for medicines. As track & trace regulations further spread and evolve, this partnership ensures that safer products reach consumers. It makes compliance for life science manufacturers simple, offering a holistic solution connecting the serialization equipment on the shop floor with an out-of-box level 3-5 track & trace solution that is configurable for the specific needs of different participants in the supply chain.

"We have been involved in product-serialization and aggregation since 2004," said Tilman Joerss, Founder and Director of Pharmalutions. "This is 15 years ahead of the EU-FMD deadline [February 2019], and it provided us with a valuable long-term perspective of the regulatory landscape and its evolutionary nature. Today, this broad experience serves our customers well in dealing with much faster approaching deadlines while safeguarding their long-run investments into product-traceability. Rapid deployment of future-proof technology. That is the key and why Movilitas.Cloud is a perfect match."

To learn more about the Movilitas.Cloud solution, please visit: https://www.movilitas.com/solutions/movilitas-cloud/

About Pharmalutions Pte LTD

Founded in 2010 in Singapore, Pharmalutions Pte Ltd is a specialist for multi-regulatory Track & Trace (T&T) based on product-serialization, with a distinct focus on pharmaceutical compliance. Pharmalutions evolved from Regional System Integrator to become a private-label in 2019. Today, Pharmalutions is an officially recognised GS1 Singapore Solution-Partner (SSP). A 10-years-history powers Pharmalutions with a unique long-term perspective on global T&T. Its deeply rooted network stretches from Europe to Asia-Pacific, across industries.

For more information, visit Pharmalutions.net or LinkedIn

About Movilitas

Movilitas is a technology leader delivering the next generation of solutions and consulting services across multiple industries to advance smart supply chain ecosystems. We are recognized as a trusted SAP partner for digital supply chain transformation. We help businesses realize new growth opportunities, adapt to today’s on-demand economy and maintain compliance. Through services, such as Movilitas.Cloud, or extensions and accelerators for SAP solutions, our clients unlock data to realize greater efficiencies and new revenue streams. For more information, visit movilitas.com, or LinkedIn, Twitter or Xing.

CONTACT: marketing@movilitas.com

Logo – https://techent.tv/wp-content/uploads/2020/09/pharmalutions-and-movilitas-cloud-deliver-serialization-solutions-for-the-asia-pacific-region.jpg

Related Links :

http://www.movilitas.com

PR Newswire

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

Leave a comment

– Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)

– Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility

HYDERABAD, India, Aug. 17, 2020 — Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research and Technology (R&T) Centre in Hyderabad, India. Sri K T Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.

Sai Life Sciences New Research & Technology Centre
Sai Life Sciences New Research & Technology Centre

Speaking on the occasion, Sri KT Rama Rao said, "I’m very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D centre. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new Research & Technology Centre but, also for their work towards the development and manufacturing of new life saving medicines."

Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility has several unique aspects such as intelligent & ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, "Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities." He further added, "We are an example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made."

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company’s capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.

Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

About Sai Life Sciences
Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

Photo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad-3.jpg  
Photo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad.jpg  
Logo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad-2.jpg

Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon'ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce
Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon’ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce